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SYNTAX score subgroups demonstrated numerically higher MACE rates in
patients with PES compared to EES (15.3% vs. 5.1%) and (30.0% vs. 15.4%)
respectively.
Patients with low and intermediate SYNTAX scores had similar TLF out-
comes at 1 year. However, the high SYNTAX score group had a significantly
higher rate of TLF in the PES group (27.5% vs. 10.3%, p=0.01).
Cardiac death was higher in patients with an intermediate SYNTAX score
in PES patients (6.8% vs.0.0%, p=0.04) as was TVMI (8.5% vs. 0.0%,
p=0.02).
Conclusion: Unprotected LM stenting with EES is feasible, safe and more
effective in the mid term, than with PES with a reduction in MACE, TLF and
cardiac death at one year.
Table 1 – One- year follow-up results
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Objectives: The PACS-HIV study is designed to evaluate the 3-year prog-
nosis of acute coronary syndrome (ACS) in HIV-infected patients (HIV+) as
compared to HIV-uninfected patients (HIV-) in a prospective observational
study. We aim to present the long term 3-year follow-up.
Methods: We enrolled consecutively 103 HIV-infected and 195 HIV-unin-
fected patients with a first episode of ACS matched for age (± 5 years), sex,
and type of ACS. The primary endpoint was the rate of major adverse cardiac
and cerebral events (MACCE), comprising cardiac death, recurrent ACS,
recurrent coronary revascularization, and stroke. 
Results: The mean age of the cohort was 49.0 ± 9.4 years and 94% were
men. At baseline, coronary risk factors were well balanced and angiographic
features were not different between both groups. MACCE at 3-year are
depicted in Table. The rate of occurrence of first MACCE at 36-months was
similar in both groups (uivariate hazard ratio [HR]=1.4, 95% CI, 0.7-2.6).
However, recurrent ACS was more frequent in HIV+ group as compared with
HIV- group (univariate HR=3.4, 95% CI, 1.3-8.8). Stratified multivariate Cox
model showed that the only factor associated with the recurrence of ACS was
HIV status with HR 7.86 for HIV+ versus HIV- (95% CI, 1.2-50.6, p= 0.03).
Conclusion: HIV-infected patients had higher recurrence of ACS despite
similar coronary risk factors, clinical, and angiographic features at baseline of
a first episode of ACS as compared to HIV-uninfected patients. Specific sec-
ondary prevention may be warranted to alleviate this risk. 
Table – MACCE at 3-year 
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Purpose: Our aim was to assess the long term prognosis value of resting
HR in a contemporary large cohort of subjects with known CAD.
Methods: Among 834 consecutive male pts hospitalized in 2001-2004 for
coronary artery disease, HR was measured in 778 pts. The median follow-up
was 7.17 years. Total mortality was predicted with a Cox proportional hazard
model
Results: Mean age (SD) was 60.2 (8.1), 144 pts (18.4%) were diabetic,
mean glycaemia was 5.9 mmol/l (2.1), 155 pts (19.8%) were smokers, mean
blood pressure was 139 (20) / 84 (11) mmHg. Mean HDL cholesterol was 43
mg/dl (11), mean LDL cholesterol124 mg/dl (39) and median triglycerides
were 147 mg/dl IQR [109-197]. Mean Cockcroft-Gault creatinine clearance
was 87 ml/min and 11 pts (1.4%) had a severe chronic renal failure (lower
than 30 ml/min). Mean left ventricular ejection fraction was 0.53 (0.13).
88.5% were on antiplatelet therapy, 75.2% on beta-blocker, 66% on statin
therapy and 54.8% on ACE inhibitors or ARB.
40.5% of pts had HR < 60 bpm, 32% HR between 60 and 69 bpm and
27.5% had HR 70 bpm. The cumulative seven-year total mortality rate was
17.8%. In the HR < 60 bpm group, mortality rate was 11.1%, whereas it was
17.3% in the group with HR - 60 bpm and < 70 bpm and 28.5% in the HR
70 bpm group (p<.001).
We performed a multivariate analysis adjusted for age, diabetes, tobacco
consumption (none; 40 pack-years; > 40 pack-years), left ventricular ejection
fraction (>0.5; 0.5 and > 0.35; 0.35), duration of CAD, ankle-brachial index
(> 0.9; 0.9 and > 0.6; 0.6), history of chronic obstructive pulmonary disease
or stroke, statin therapy and coronary revascularization. For every 5 bpm
increase in resting heart rate, there was a significant 11% increase in all-cause
death (95% CI [4%; 18%] p=0.002).
Conclusion: HR is a strong and independent long term predictor factor of
all-cause death in CAD. A close control of HR should be promoted to improve
long term prognosis in coronary pts.
EES PES P
All cause death 2.9% 6.4% 0.13
Cardiac death 1.2% 4.7% 0.05
Target vessel myocardial infarction 4.1% 8.7% 0.08
Clinically driven target-lesion revascularization 2.9% 5.8% 0.19
Clinically indicated target vessel 
revascularization
7.0% 13.4% 0.05
Target lesion failure 6.4% 14.0% 0.02












Major adverse cardiac events 17 (16.8†) 29 (15.1†) 1.4 [0.7-2.6]
Cardiovascular death 2 (3.0†) 3 (1.6†) 2.0 [0.4-9.9]
Recurrent ACS 12 (11.9†) 11 (5.8†) 3.4 [1.3-8.8]
Recurrent coronary 
revascularization
12 (11.8†) 24 (12.6†) 1.1 [0.5-2.2]
Target lesion revascularization 8 (7.8†) 17 (9.0†) 0.9 [0.4-2.1]
Target vessel revascularization 11 (10.8†) 20 (10.5†) 1.1 [0.5-2.3]
